Retrospective Study
Copyright ©The Author(s) 2023.
World J Gastrointest Surg. Nov 27, 2023; 15(11): 2500-2512
Published online Nov 27, 2023. doi: 10.4240/wjgs.v15.i11.2500
Table 2 Clinicopathological data and univariate analysis of early postoperative complications in patients with distl gastric cancer
FactorsWith early postoperative complications (%)Without early postoperative complications (%)χ2/tP value
Age (yr)71 (60.5-74)63 (5-70)-2.140.032
Weight66.15 ± 11.0865.85 ± 10.010.1180.906
Height168.20 ± 6.869165.52 ± 7.4611.6140.109
BMI23.312 ± 3.2224.00 ± 3.11-0.9050.367
Hemoglobin129 (100.5-145)128.5 (114.25-144.25)-0.3420.732
Albumin39.9 (36.35-42.75)41.35 (38.2-45)-1.7540.08
Prealbumin18.9 (14.4-22.5)21.45 (17.2-25.3)-2.1990.028
Alpha fetoprotein3.02 (2.285-4.465)2.495 (1.815-3.9225)-1.3830.167
Carcinoembryonic antigen2.065 (1.4625-2.8625)1.76 (1.265-3.38)-0.5110.609
CA1997.3 (5-20.55)9.04 (5.9925-16.05)-0.3260.744
CA1259.66 (6.325-19.385)8.685 (6.3-12.5)-0.7810.435
Number of positive lymph nodes2 (0-8)0.5 (0-6.25)-0.6430.526
Number of lymph node resections29 (21-40)28 (22-34)-0.3520.725
Tumor maximum diameter4.5 (3-6)4 (2.425-5.5)-0.8170.414
Surgical time250 (205-265)240 (210-282)-0.1410.888
Blood loss50 (35-100)50 (50-100)-0.2360.814
Organizational type10.6640.099
Poorly differentiated adenocarcinoma9 (27.3)24 (72.7)
Moderate to poorly differentiated adenocarcinoma7 (12.3)5 (92.3)
Moderately differentiated adenocarcinoma1 (7.7)12 (85.7)
Medium to high differentiation adenocarcinoma1 (12.5)7 (87.5)
Highly differentiated adenocarcinoma0 (0)5 (100)
Diffuse large B-cell carcinoma1 (100)0 (0)
Signet ring cell carcinoma2 (14.3)12 (87.5)
General type3.2020.921
Concave type2 (18.2)9 (81.8)
Shallow concave type1 (5.3)18 (94.7)
Superficial uplift type1 (14.3)6 (86.7)
Shallow flat type0 (0)1 (100)
Nodular type1 (33.3)2 (66.7)
Infiltrating ulcer type2 (15.4)11 (84.6)
Ulcerative type11 (19)47 (81)
Protuberant type2 (20)8 (80)
Diffuse infiltrative type1 (11.1)8 (88.9)
ASA0.4280.934
0 (0)1 (100)
10 (15.6)54 (84.4)
11 (16.9)54 (83.1)
0 (0)1 (100)
Sex0.210.647
Male17 (16.8)84 (83.2)
Female4 (13.3)26 (86.7)
Transfusion11.3420.001
Yes17 (27.4)45 (72.6)
No4 (5.8)65 (94.2)
P stage3.1430.37
6 (11.5)46 (88.5)
5 (22.7)17 (77.3)
10 (19.6)41 (80.4)
0 (0)6 (100)
hypertension1.5810.001
Yes14 (31.1)31 (68.9)
No7 (8.1)79 (91.9)
Diabetes9.270.002
Yes10 (37)17 (63)
No11 (10.6)93 (89.4)
Smoking history3.2620.071
Yes1 (3.4)28 (96.6)
No20 (19.6)82 (80.4)
History of drinking0.0170.896
Yes6 (15.4)33 (84.6)
No15 (16.3)77 (83.7)
History of abdominal surgery7.1990.007
Yes8 (38.1)13 (61.9)
No13 (11.8)97 (88.2)
Laparoscopy0.0020.962
Yes11 (16.2)57 (83.8)
No10 (15.9)53 (84.1)
Robot surgery0.0020.962
Yes10 (15.9)53 (84.1)
No11 (16.2)57 (83.8)
Intraperitoneal perfusion chemotherapy0.0010.971
Yes6 (16.2)31 (83.8)
No15 (16.0)79 (84.0)
R07.4660.006
Yes18 (14.3)108 (85.7)
No2 (40)3 (60)
Vascular invasion0.2420.622
Yes11 (14.7)64 (85.3)
No10 (17.9)46 (82.1)
Lymphatic invasion1.5660.212
Yes4 (10)36 (90)
No17 (18.7)74 (81.3)
Combined organectomy0.2750.6
Yes19 (15.6)103 (84.4)
No2 (22.2)7 (77.8)
Liver0.0170.897
Yes1 (14.3)6 (85.7)
No20 (16.1)104 (83.9)
Lung0.7880.375
Yes0 (0)4 (100)
No21 (16.5)106 (83.5)
Kidney0.7880.375
Yes0 (0)4 (100)
No21 (16.5)106 (83.5)
Heart2.1930.144
Yes5 (27.8)13 (72.2)
No16 (14.2)97 (85.8)
Brain2.3290.127
Yes4 (30.8)9 (69.2)
No17 (14.4)101 (85.6)
T stage0.470.493
16 (13)40 (87)
≥ 215 (17.6)70 (82.4)
N stage0.6390.888
09 (14.3)54 (85.7)
12 (13.3)13 (86.7)
23 (16.7)15 (83.3)
37 (20)28 (80)
M stage1.20.273
021 (16.8)104 (83.2)
10 (0)6 (100)